PLAU Antikörper (AA 60-90)

Produktnummer ABIN3032245

Produktdetails anti-PLAU Antikörper

Target: PLAU (Plasminogen Activator, Urokinase (PLAU))

Bindungsspezifität: AA 60-90

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PLAU Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Aufreinigung: Purified

Immunogen: A portion of amino acids 60-90 from the human protein was used as the immunogen for this Urokinase antibody.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Titration of the Urokinase antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:10-1:50,Flow Cytometry: 1:10-1:50

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the Urokinase antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Details zu PLAU

Target: PLAU (Plasminogen Activator, Urokinase (PLAU))

Andere Bezeichnung: Urokinase (PLAU Produkte)

Synonyme: PLAU antikoerper, u-PA antikoerper, ATF antikoerper, BDPLT5 antikoerper, QPD antikoerper, UPA antikoerper, URK antikoerper, uPA antikoerper, UPAM antikoerper, plasminogen activator, urokinase antikoerper, urokinase-type plasminogen activator antikoerper, PLAU antikoerper, CpipJ_CPIJ002131 antikoerper, CpipJ_CPIJ006543 antikoerper, CpipJ_CPIJ013396 antikoerper, CpipJ_CPIJ013623 antikoerper, Plau antikoerper

Hintergrund: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.

UniProt: P00749

Pathways: Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagie, Smooth Muscle Cell Migration